Purpose

RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor (ETI) that resulted in a modification or discontinuation of standard ETI dosing.

Condition

Eligibility

Eligible Ages
Over 6 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

RETRIAL-Mental Health: - PWCF age 6 years and up (if age is < 12 years old, the PWCF's caregiver will complete daily diaries and surveys; see "Caregiver Participant Inclusion Criteria" below) - Eligible for VTD and intending to take it - Experienced new or worsening mental health symptoms after initiating ETI, which led to one of the following changes in treatment to currently taking: 1. No modulators 2. A modulator other than ETI 3. A flipped dose of ETI 4. A reduced dose of ETI - Willing to delay first VTD dose for short period of time to complete the Baseline assessments - Has access to a smart device (phone, tablet, etc.) capable of receiving messages with survey links - Is English-speaking. RETRIAL-LIVER: - A person with CF age 6 years and up - Eligible for VTD and intending to take it - Experienced drug-induced liver injury (as defined by local care team) after initiating ETI, which led to one of the following changes in treatment to currently taking: 1. no modulators; or 2. a modulator other than ETI; or 3. a reduced or altered dose of ETI; - Willing to delay first VTD dose for short period of time to complete the Baseline assessments - Has access to a smart device (phone, tablet, etc.) capable of receiving messages with survey links - Is English-speaking.

Exclusion Criteria

RETRIAL-Mental Health: - Cannot access VTD - Currently, or prior history of, taking VTD - Unable or unwilling to follow protocol - If <12 years old, having another <12-year-old person in the same household consented into the study - Is actively listed on any transplant list, or within 3 months post-transplant surgery - Is currently pregnant (test not required) - Anticipated change in CF Care Centers in the next 6 months - Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data. RETRIAL-LIVER: - Cannot access VTD - Currently, or prior history of, taking VTD - Unable or unwilling to follow protocol - If <12 years old, having another <12-year-old person in the same household consented into the study - Any severe, decompensated liver disease (e.g. Child-Pugh, Class C) - Is actively listed on any transplant list, or within 3 months post-transplant surgery (any organ), or history of liver transplant - Is currently pregnant (test not required) - Anticipated change in CF Care Centers in the next 6 months - Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data. Caregiver Participant: Inclusion Criteria: - Is a primary, daily caregiver of a person with CF under the age of 12 enrolled in the study - Has access to smart device (phone, tablet, etc.) capable of receiving messages with survey links - Is able to read and complete surveys and Daily Diary in English. Exclusion Criteria: - Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Other

Arm Groups

ArmDescriptionAssigned Intervention
RETRIAL-Mental Health People with CF ages 6 and up with a history of new or worsening mental health symptoms (such as depression, anxiety, mood, sleep) while on elexacaftor/tezacaftor/ivacaftor (ETI) requiring discontinuation or change from standard dosing who start taking vanzacaftor/tezacaftor/deutivacaftor (VTD).
  • Other: RETRIAL-Mental Health
    Participants will complete: daily diaries for 6 weeks, from about 2 weeks prior to starting VTD to about 4 weeks after; biweekly surveys, from about 2 weeks prior to starting VTD to 6 months after, and 2 quarterly surveys (at 9mo and 12mo post-initiation of VTD).
RETRIAL-Neuro People with CF from RETRIAL-Mental Health who experienced new/worsening neurocognitive symptoms (such as brain fog or memory problems) while taking elexacaftor/tezacaftor/ivacaftor (ETI).
  • Other: RETRIAL-Neuro
    Participants will complete a neurocognitive assessment prior to starting VTD and 28 days after.
RETRIAL-Liver People with Cystic Fibrosis ages 6 and up with a history of drug-induced liver injury (such as elevated liver enzymes) attributed to elexacaftor/tezacaftor/ivacaftor (ETI) requiring dose modification or discontinuation who start taking vanzacaftor/tezacaftor/deutivacaftor (VTD).
  • Other: RETRIAL-Liver
    Participants may have a research liver function test done prior to starting VTD and 28 days after, if not done clinically. Participants will complete surveys: before starting VTD, a month after, and quarterly (at about 3, 6, 9, and 12 months) following VTD initiation.

Recruiting Locations

University of Alabama at Birmingham
Birmingham 4049979, Alabama 4829764 35233
Contact:
Kathryn Monroe
kathrynmonroe@uabmc.edu

More Details

Status
Recruiting
Sponsor
Boston Children's Hospital

Study Contact

Evelyn Bord, BS
617-919-6154
evelyn.bord@childrens.harvard.edu

Detailed Description

RETRIAL is a prospective, longitudinal, observational, multi-site study of people with Cystic Fibrosis (PWCF) ages 6 and up who had to either change how they took or stop taking elexacaftor/tezacaftor/ivacaftor (ETI) due to new or worsening mental health/cognitive symptoms (such as depression, anxiety, mood, sleep, and/or brain fog/memory problems) and/or liver issues (elevated liver enzymes) while taking the standard dose, and who plan to start taking vanzacaftor/tezacaftor/deutivacaftor (VTD).

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.